Anteris Technologies announces US IPO filing

Anteris Technologies (ASX:AVR), a company specializing in structural heart solutions, has announced that its U.S. subsidiary, Anteris Technologies Global Corp. (ATGC), has submitted a Registration Statement on Form S-1 to the U.S. Securities and Exchange Commission (SEC). This filing is for a proposed initial public offering (IPO) of ATGC's common stock in the United States. The exact amount of stock and price range are yet to be determined, and the offering will depend on market conditions. Upon successful re-domiciliation to the U.S., ATGC plans to list its stock on the Nasdaq Global Select Market under the symbol 'AVR'.

Anteris Technologies plans US market expansion

Anteris Technologies has announced its U.S. subsidiary's intention to launch an initial public offering (IPO) on the Nasdaq Global Select Market. This is part of a larger strategy to re-domicile operations to the United States through schemes of arrangement involving its shareholders and optionholders. The company focuses on the development of innovative solutions for aortic stenosis, particularly through its leading product, the DurAVR® transcatheter heart valve (THV), which incorporates proprietary anti-calcification technology. Anteris's expansion into the U.S. market aligns with its goal to increase its global footprint and enhance its capabilities in the structural heart disease sector. The company is working with major financial institutions including TD Cowen, Barclays, and Cantor to manage the offering.

Executive insights on US market entry

Anteris Technologies sees this IPO as a significant step in our strategic plan to expand our presence in the U.S. market and enhance our capabilities in delivering innovative solutions for structural heart disease. By re-domiciling and listing on the Nasdaq, we aim to broaden our investor base and increase our visibility in the global healthcare sector.